An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
Cutera, Inc. (NASDAQ: CUTR) announced plans to offer $100 million in convertible senior notes due 2029 to qualified institutional buyers. The offering may include an additional $20 million at the initial purchasers' option. Proceeds will cover the costs of capped call transactions and fund general corporate purposes, including working capital, acquisitions, and potential stock repurchases. The notes are unsecured and will be convertible into cash or common stock. Notably, this offering aims to mitigate potential dilution of shares upon conversion.
Positive
Offering $100 million of convertible senior notes may enhance liquidity.
Intended use of funds includes potential acquisitions and strategic transactions.
Capped call transactions expected to reduce potential dilution of common stock.
Negative
Convertible notes could lead to dilution if converted into shares.
Market reactions may cause fluctuations in Cutera's stock price.
BRISBANE, Calif--(BUSINESS WIRE)--
Cutera, Inc. (Nasdaq: CUTR) (“Cutera” or the “Company”), a leading provider of aesthetic and dermatology solutions, today announced that it intends to offer, subject to market conditions and other factors, $100 million aggregate principal amount of convertible senior notes due 2029 (the “notes”) in a private placement to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the “Securities Act”). Cutera also intends to grant the initial purchasers of the notes an option to purchase up to an additional $20 million aggregate principal amount of the notes.
The notes will be general senior, unsecured obligations of Cutera and will accrue interest payable semiannually in arrears. The notes will be convertible into cash, shares of Cutera’s common stock (“common stock”) or a combination of cash and shares of Cutera’s common stock, at Cutera’s election. The interest rate, initial conversion rate and other terms of the notes will be determined at the time of pricing of the offering.
Cutera intends to use a portion of the net proceeds from the offering to pay the aggregate cost of the capped call transactions described below. If the initial purchasers exercise their option to purchase additional notes, Cutera expects to use a portion of the net proceeds from the sale of such additional notes to enter into additional capped call transactions. Cutera intends to use the remainder of net proceeds from the offering for general corporate purposes, which may include placements of AviClear, working capital, capital expenditures, potential acquisitions and strategic transactions, potential repurchases of its common stock and potential repurchases or exchanges of its existing convertible senior notes.
In connection with the pricing of the notes, Cutera expects to enter into capped call transactions with one or more of the initial purchasers and/or their respective affiliates and/or other financial institutions (the “option counterparties”). The capped call transactions are expected generally to reduce potential dilution to Cutera’s common stock upon any conversion of notes, with such reduction subject to a cap. If the initial purchasers exercise their option to purchase additional notes, Cutera expects to enter into additional capped call transactions with the option counterparties.
Cutera expects that, in connection with establishing their initial hedges of the capped call transactions, the option counterparties or their respective affiliates may enter into various derivative transactions with respect to Cutera’s common stock and/or purchase shares of Cutera’s common stock concurrently with or shortly after the pricing of the notes. This activity could increase (or reduce the size of any decrease in) the market price of Cutera’s common stock or the notes at that time.
In addition, Cutera expects that the option counterparties or their respective affiliates may modify their hedge positions by entering into or unwinding various derivatives with respect to Cutera’s common stock and/or purchasing or selling Cutera’s common stock or other securities of Cutera in secondary market transactions following the pricing of the notes and prior to the maturity of the notes (and are likely to do so on each exercise date for the capped call transactions). This activity could also cause or prevent an increase or a decrease in the market price of Cutera’s common stock or the notes, and to the extent the activity occurs during any observation period related to a conversion of notes, this could affect the value of the consideration that a noteholder will receive upon conversion of its notes.
Neither the notes, nor any shares of Cutera’s common stock potentially issuable upon conversion of the notes, have been, nor will be, registered under the Securities Act or any state securities laws and, unless so registered, may not be offered or sold in the United States absent registration or an applicable exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and other applicable securities laws.
This press release is neither an offer to sell nor a solicitation of an offer to buy any securities, nor shall it constitute an offer, solicitation or sale of the securities in any jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such jurisdiction.
